Deep Science Ventures Custom Case Solution & Analysis

Evidence Brief: Deep Science Ventures (DSV)

1. Financial Metrics

Venture Builder Capital: DSV operates on a model where it provides roughly 250,000 GBP to 500,000 GBP in total funding per venture created through the initial phases.
Equity Stake: DSV typically takes a 15 percent to 20 percent equity stake in companies formed within its program in exchange for the stipend and initial investment.
Founder Stipend: Founders-in-Residence (FIRs) receive a monthly stipend of approximately 3,000 GBP during the initial scoping phase to allow full-time commitment.
Fund Size: Transitioning from a balance-sheet-led model to a dedicated 30 million GBP to 50 million GBP fund structure to support the creation of 30 to 40 companies.
Success Rate: Early data suggests a higher survival rate for DSV-originated companies compared to traditional pre-seed benchmarks, with over 30 companies created across sectors like agriculture, energy, and pharmaceuticals since 2016.

2. Operational Facts

Process Methodology: The DSV model follows a four-stage process: Scoping (identifying the problem), Recruitment (finding the scientists), Team Formation (matching talent), and Spin-out (incorporation and seed funding).
Talent Sourcing: Focuses on PhDs and post-doctoral researchers rather than traditional entrepreneurs. DSV receives over 1,000 applications for roughly 30 to 40 FIR spots annually.
Timeframe: The journey from scoping to spin-out typically spans 6 to 12 months.
Geography: Headquartered in London, UK, but recruiting globally and operating across multiple regulatory jurisdictions.
Sector Focus: Operates in four core domains: Pharmaceuticals, Climate, Agriculture, and Computation.

3. Stakeholder Positions

Dominic Falcao and Mark Hammond (Founders): View the current venture capital model as reactive and inefficient for deep science. They advocate for a proactive, outcome-led approach to venture creation.
Founders-in-Residence (FIRs): High-level scientists who seek a path to commercialize expertise without the traditional risks of early-stage solo entrepreneurship.
Limited Partners (LPs): Traditional investors who are wary of the venture builder model due to its high overhead and pre-seed risk profile compared to standard VC funds.
University Partners: Institutions that see DSV as a potential vehicle for technology transfer but remain protective of intellectual property (IP) and academic timelines.

4. Information Gaps

Long-term IRR: Because the oldest portfolio companies are less than eight years old, there is no realized Internal Rate of Return (IRR) data to prove the model to institutional LPs.
Follow-on Funding Success: Limited data on the percentage of DSV companies that successfully close Series A rounds from external, non-affiliated investors.
IP Ownership Details: Specifics on how DSV handles IP generated during the scoping phase before a legal entity is incorporated are not fully detailed.

Strategic Analysis

1. Core Strategic Question

How can DSV scale its outcome-led venture creation model into a sustainable institutional asset class while maintaining the high-touch scientific rigor required for deep-tech success?
The central dilemma is the tension between the high operational cost of building companies from scratch and the need for a scalable investment vehicle that attracts institutional capital.

2. Structural Analysis

Value Chain Analysis: DSV moves upstream of the traditional VC. By controlling the team formation and problem definition, they reduce the adverse selection risk that plagues traditional seed investing. However, this increases operational expenditure significantly.
Jobs-to-be-Done: For the scientist, the job is to de-risk the transition from lab to market. For the investor, the job is to access high-quality, non-obvious deep-tech deals. DSV acts as the bridge, but the cost of the bridge is currently higher than the toll collected via equity.
Competitive Landscape: Traditional accelerators (Y Combinator) provide capital to existing teams. DSV creates the team. This uniqueness is a moat, but it is difficult to automate or scale without losing the bespoke mentorship that Hammond and Falcao provide.

3. Strategic Options

Option 1: The Sector-Specific Fund Model. Raise dedicated funds for each of the four core domains.
- Rationale: Allows for specialized LPs and deeper technical expertise.
- Trade-offs: Increases administrative complexity and requires four times the fundraising effort.
- Resources: Requires hiring domain-specific Managing Directors for each fund.
Option 2: The Partnership/Franchise Model. Partner with large corporations or governments to build companies on their behalf for a management fee plus equity.
- Rationale: Provides immediate cash flow to cover the high operational costs of the FIR stipends.
- Trade-offs: Risks losing strategic independence; corporate partners may demand right-of-first-refusal on spin-outs.
- Resources: Requires a dedicated business development team to manage institutional relationships.
Option 3: Pure-Play Venture Builder. Stay small, focus on 10 high-conviction companies per year, and maximize equity value.
- Rationale: Preserves the quality and culture of the DSV method.
- Trade-offs: Limited upside; may be out-competed by larger, better-funded builders like Flagship Pioneering.
- Resources: Minimal additional hiring; relies on the founders' personal bandwidth.

4. Preliminary Recommendation

DSV must pursue Option 1: The Sector-Specific Fund Model. The current balance-sheet-constrained model is not sustainable for the capital-intensive nature of deep science. By institutionalizing the model into sector-specific funds, DSV can attract larger LPs, provide follow-on capital to its best winners, and build a track record that justifies the venture builder overhead. This path solves the capital gap while maintaining the integrity of the scientific process.

Implementation Roadmap

1. Critical Path

Month 1-3: Fund Structuring. Establish the legal and regulatory framework for a Sector-Specific Fund (starting with Climate or Pharma). Define the fee structure to ensure it covers the FIR stipends and operational costs.
Month 4-6: LP Roadshow. Target family offices and sovereign wealth funds interested in impact and deep-tech. Focus on the de-risking aspect of the DSV model as the primary selling point.
Month 7-9: Talent Acquisition. Recruit two Associate Directors per sector to manage the FIRs, reducing the operational burden on Falcao and Hammond.
Month 10-12: Launch Pilot Cohort. Execute the first fund-backed scoping phase with 10 FIRs in a single sector to prove the economics of the new fund structure.

2. Key Constraints

Talent Bottleneck: The availability of scientists who possess both the technical depth and the commercial appetite to lead a company is the primary constraint. Scaling recruitment is non-trivial.
LP Education: Institutional investors are accustomed to seeing teams with prototypes. DSV asks them to invest in a process that creates teams. This shift in mindset is a significant hurdle.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of fundraising failure, DSV should secure one anchor corporate partner for the first fund. This provides a signal of commercial validity to other LPs. If the fund does not reach its 30 million GBP target within 12 months, the contingency plan is to revert to a project-based fee model with governments (Option 2) to maintain the FIR stipends while delaying the scale-up of the internal team. Execution success depends on the ability to institutionalize the founders' intuition into a repeatable playbook that Associate Directors can execute.

Executive Review and BLUF

1. BLUF (Bottom Line Up Front)

DSV must transition from a boutique venture builder to an institutional fund manager to survive. The current model, while scientifically superior to traditional VC, is operationally fragile and capital-constrained. By raising sector-specific funds, DSV can cover its high overhead, provide follow-on capital, and scale its impact. Success depends on shifting the investor narrative from team-picking to process-driven venture creation. The window to establish dominance in the European deep-tech ecosystem is narrow; speed in fundraising is now as critical as the science itself.

2. Dangerous Assumption

The most consequential unchallenged premise is that high-level scientific talent can be consistently coached into high-performance CEOs. The DSV model assumes a talent conversion rate that may not hold as the founders move further away from day-to-day mentorship. If the conversion rate of scientists to founders drops by even 20 percent, the unit economics of the fund will collapse due to the high cost of the pre-seed stipend phase.

3. Unaddressed Risks

Adverse Selection in Scale: As DSV increases its intake to 40 plus FIRs per year, the quality of the scoping phase may diminish, leading to weaker spin-outs that fail to attract Series A capital. (Probability: High; Consequence: Critical).
Regulatory Divergence: Operating across Climate and Pharma involves disparate regulatory hurdles. A failure to navigate a specific regulatory pathway in one sector could tarnish the DSV brand across all funds. (Probability: Medium; Consequence: High).

4. Unconsidered Alternative

The analysis overlooked a Joint Venture (JV) with an established Tier-1 VC. Instead of raising an independent fund, DSV could act as the exclusive venture-creation arm for a firm like Sequoia or IP Group. This would provide immediate access to infinite capital and exit networks, though at the cost of long-term equity upside and brand independence. This path would eliminate the fundraising risk entirely and allow the founders to focus exclusively on the scientific process.